ialurillogo

HEALTHCARE PROFESSIONALS

Slide background

About

Welcome to iAluRil.co.uk

ialDiagram2iAluRil is a medical device presented in a 50ml latex free pre-filled syringe with a Luer-Lock adaptor for easy use.

EACH PRE-FILLED SYRINGE IS FOR ONE PATIENT ONLY.
IALURIL® Prefill – 50 ml pre-filled syringe is steam sterilized.
IALURIL® Prefill – 50 ml pre-filled syringe is Latex Free.
Luer-Lock Adapter is sterilized using ethylene oxide.1

iAluRil contains  two active components: 800 mg/50 ml sodium hyaluronate (1.6%) and 1 g /50 ml sodium chondroitin sulfate (2%).

iAluRil can be used for the treatment of:
– Interstitial cystitis/painful bladder syndrome
– Recurrent urinary tract infections
– Chemical-/radiation-induced cystitis (including BCG)

iAluRil® is the first intravesical GAG replacement therapy to combine one of the most abundant sulfated GAG molecules located on the bladder wall,2 chondroitin sulfate, with the most integral component of the GAG layer,3 hyaluronic acid. This combination is designed to facilitate faster and more effective restoration of the bladder epithelium.

iAluRil contains 20-times the concentration of hyaluronic acid compared with the conventional therapy (Cystistat®; Teva UK Ltd, West Yorkshire, UK), which contains 0.08% hyaluronic acid, this increase allows for more association sites for a core protein to bind to. Through a link protein the core protein can bind to sulfated glycosaminoglycans such as chondroitin sulfate. Chondroitin sulfate then functions to bind water molecules on the surface of the epithelial lining of the bladder in order to maintain the waterproof and impermeable nature of a healthy bladder.2 Therefore, by increasing the concentration of hyaluronic acid it ultimately increases the number of water molecules bound providing more help in maintaining the healthy state of the bladder.

Available in hospital and community practice. Now available on FP10.

Manufactured by IBSA FARMACEUTICI ITALIA SRL logoIBSAIT

Under license from NTC S.r.l ntclogo

References: 1) iAluRil Prefill Patient Information. 2) Hurst RE et al. Functional and Structural Characteristics of the Glycosaminoglycans of the Bladder Luminal Surface. J Urol 1987; 138 (2): 433-437. 3) Stryer L. Biochemistry – 4th Edition. W.H. Freeman & Company; 1995.

 

For further information please call: 01730 231148, email: info@aspirepharma.co.uk or visit www.aspirepharma.co.uk

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Aspire Pharma Ltd on 01730 231148
Revision reference – iAluRil_2__27/06/2017

Save

Save